RNS & Investor News

Result of AGM

08 August 2024

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care announces that at the AGM held earlier today, all resolutions were duly passed.

The full voting results will be available on the website in due course here: https://www.optibiotix-ir.com/content/investors/

 

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook below
Stephen O'Hara, Chief Executive  
  
Cairn Financial Advisers LLP (NOMAD)Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti 
Peterhouse Capital Limited (Broker) Tel: 020 7220 9797
Duncan Vasey / Lucy Williams  
  
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy  

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.